Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial

OBJECTIVES: To determine the therapeutic equivalence and safety of once daily (OD) versus three times daily (TID) dosing of a total daily dose of 3 g Salofalk (mesalazine) granules in patients with active ulcerative colitis. DESIGN: A randomised, double-blind, double-dummy, parallel group, multicent...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Kruis, W, Kiudelis, G, Rácz, I, Gorelov, I A, Pokrotnieks, J, Horynski, M, Batovsky, M, Kykal, J, Boehm, S, Greinwald, R, Mueller, R
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2009
Konular:
Inflammatory Bowel Disease
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3269751/
https://ncbi.nlm.nih.gov/pubmed/18832520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2008.154302
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller